INAB vs INTS

IN8bio, Inc. vs Intensity Therapeutics, Inc. — Valuation Comparison 2026

INAB

Biological Products, (No Diagnostic Substances)
IN8bio, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.87
Last close
Models
7/13
Active
VS

INTS

Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$4.39
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType INAB Fair ValueINAB Upside INTS Fair ValueINTS Upside
Bayesian DCF Intrinsic $1.54 -17.5% $3.31 -24.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.21 -85.8% $0.26 -95.1%
Dynamic NAV Asset-Based $3.60 +92.5% $8.03 +82.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INAB vs INTS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INAB vs INTS — Which Stock Is More Undervalued?

INTS scores higher with a 3.7/10 quality rating vs INAB's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IN8bio, Inc. (INAB) and Intensity Therapeutics, Inc. (INTS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INAB currently trades at $1.87 with a QOC of 3.2/10, while INTS trades at $4.39 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).